Catalyst Calendar

Phase 2 results for acne vulgaris candidate

Zirconium-89 PET imaging agent for renal cell carcinoma

COAST pivotal trial topline results

6 of 7 Medicare Administrative Contractors have published RECELL payment rates; final MAC publication outstanding

Collagen dermal matrix clinical study top-line results

Completion of enrolment in the SOLVE-CRT pivotal trial

Primary completion expected for NCT06750419. Indication: {"Clear Cell Renal Cell Carcinoma"}

Company expects to receive approximately AUD $7.5M in R&D Tax Incentive credits for FY2026. [Source: AUD $3.7M Income Tax Refund Received, 2026-06-30]

Settlement terms allow competing generics at end of FY2026. Revenue headwind for dermatology segment

Phase 1 FIH completed 2025, all 3 cohorts cleared by Safety Review Committee

Comprehensive data from 10-subject Phase 2b therapeutic arm. Top-line showed reduced viral load and symptoms

Initial shipment of Dr Watson® medicinal cannabis flower SKUs to Costa Rica under the expanded Remidose LATAM supply agreement expected to exceed AUD $500,000. [Source: Expands LATAM Footprint First Supply Agreement Costa Rica, 2026-05-10]

BCAL's multi-cancer early detection test is expected to launch in June 2026, representing a key commercial milestone following the platform infrastructure launch. [Source: BCAL Launches Early Detection Cancer Platform, 2026-05-19]

Court decision on Cosette's appeal of the October 2025 judgment, with appeal hearing completed on 2-3 June 2026 and decision reserved. [Source: Mayne Pharma receives $14.4m for legal costs from Cosette, 2026-06-05]

The recommended INN status for xaranetide (ARG-007) is expected to be published shortly following WHO confirmation. [Source: WHO Confirms Xaranetide as INN for ARG-007, 2026-06-09]

Update on Medicare/insurance reimbursement pathway for XV Technology

Phase III CLARIFY imaging trial recruitment completion expected 2026

FDA-agreed Phase III of Cu-64 SARTATE imaging in neuroendocrine tumours, recruitment starting 2026

Pivotal trial of apolipoprotein A-I in acute coronary syndrome, data expected 2026

Southern hemisphere influenza vaccine revenue for 2026 season

Working with FDA on pathway for US approval in SR-aGvHD

Continued patient dosing and follow-up data in retinitis pigmentosa type 11

Progress on new endoscope reprocessing platform regulatory pathway

Continued follow-up data from ADAPT tissue-engineered aortic valve trial

7th MAC to publish RECELL payment rates — 6 of 7 already confirmed

First European marketing authorization filing for NEURACTHEL ACTH therapy, representing Clinuvel's expansion into neurological/endocrinological disorders.

Connected oral appliance therapy study supporting efficacy monitoring claim for FDA 510(k)

Covers both Breast C and D density women (~50% of screened population). Following 800-patient study

FDA approved Aug 2024, launched May 2025 via TruPharma. US market >US$37.4M annually

Primary completion expected for NCT06939920. Indication: {"Respiratory Failure Requiring Non Invasive Ventilation"}

Interim efficacy data in rare paediatric neurological condition

First-in-human safety data for chlorotoxin CAR-T in glioblastoma

FDA review of OncoSil™ HDE application for distal cholangiocarcinoma is expected to be completed within approximately 45 days from the submission date of July 2, 2026. [Source: OncoSil Medical Files for FDA Approval, 2026-07-02]

H1 showed record revenue $124.8M (+28.4% YoY). Market watching for new contract announcements and margin trajectory

H1 revenue A$5.445B, EBITDA A$907M. Market expects further margin improvement

GTG has multiple outstanding periodic reports due by 29 August 2026. [Source: Long Term Suspended Entities, 2026-07-10]

Phase 2 progress for hernia repair indication

Market questioning whether $48M FY26 EBIT guidance is achievable

All 11 Technegas system installations across University Hospitals Cleveland network scheduled to be completed within weeks of the July 2026 agreement. [Source: Immediate 11-Site Technegas Rollout at University Hospitals, 2026-07-14]

Primary completion expected for NCT06704867. Indication: {"Endoscopic Ultrasound"}

Noxopharm expects to hold a pre-IND meeting with the US FDA within two months of the formal request to discuss the clinical development pathway for SOF-SKN™. [Source: Pre-IND meeting request with US FDA, 2026-07-06]